Lombard Medical was developing solutions for the $1.1 billion dollar abdominal aortic aneurysm (AAA) repair market. AAAs are balloon-like enlargements of the aorta which, if left untreated, may rupture and cause death. The company developed an endovascular stent graft, which was approved in the US, Europe and Japan. Lombard was a VIPE (Venture Investment in Public Equity). The company was acquired by MicroPort Scientific Corporation in a restructuring transaction in April 2018.